GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sailong Pharmaceutical Group Co Ltd (SZSE:002898) » Definitions » Return-on-Tangible-Equity

Sailong Pharmaceutical Group Co (SZSE:002898) Return-on-Tangible-Equity : 1.53% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Sailong Pharmaceutical Group Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sailong Pharmaceutical Group Co's annualized net income for the quarter that ended in Mar. 2024 was ¥6.5 Mil. Sailong Pharmaceutical Group Co's average shareholder tangible equity for the quarter that ended in Mar. 2024 was ¥423.4 Mil. Therefore, Sailong Pharmaceutical Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 1.53%.

The historical rank and industry rank for Sailong Pharmaceutical Group Co's Return-on-Tangible-Equity or its related term are showing as below:

SZSE:002898' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -12.77   Med: 7.56   Max: 49.53
Current: 1.88

During the past 11 years, Sailong Pharmaceutical Group Co's highest Return-on-Tangible-Equity was 49.53%. The lowest was -12.77%. And the median was 7.56%.

SZSE:002898's Return-on-Tangible-Equity is ranked better than
81.98% of 1304 companies
in the Biotechnology industry
Industry Median: -46.86 vs SZSE:002898: 1.88

Sailong Pharmaceutical Group Co Return-on-Tangible-Equity Historical Data

The historical data trend for Sailong Pharmaceutical Group Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sailong Pharmaceutical Group Co Return-on-Tangible-Equity Chart

Sailong Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.71 -12.77 -4.92 -8.46 2.26

Sailong Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.02 -0.20 1.26 4.92 1.53

Competitive Comparison of Sailong Pharmaceutical Group Co's Return-on-Tangible-Equity

For the Biotechnology subindustry, Sailong Pharmaceutical Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sailong Pharmaceutical Group Co's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sailong Pharmaceutical Group Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Sailong Pharmaceutical Group Co's Return-on-Tangible-Equity falls into.



Sailong Pharmaceutical Group Co Return-on-Tangible-Equity Calculation

Sailong Pharmaceutical Group Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=9.534/( (421.884+423.149 )/ 2 )
=9.534/422.5165
=2.26 %

Sailong Pharmaceutical Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=6.496/( (423.149+423.582)/ 2 )
=6.496/423.3655
=1.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Sailong Pharmaceutical Group Co  (SZSE:002898) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Sailong Pharmaceutical Group Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Sailong Pharmaceutical Group Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Sailong Pharmaceutical Group Co (SZSE:002898) Business Description

Traded in Other Exchanges
N/A
Address
No. 47, Haibin South Road, 2nd Floor, Everbright International Trade Center, Guangdong Province, Zhuhai, CHN, 519015
Zhuhai Sailong Pharmaceutical Co Ltd is the pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.
Executives
Tang Lin Director
Long Zhi Xiang Director
Deng Yong Jun Supervisors
Zhou Bei Supervisors
Li Jian Feng Directors, executives

Sailong Pharmaceutical Group Co (SZSE:002898) Headlines

No Headlines